Global Romiplostim Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Romiplostim market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Romiplostim is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Romiplostim is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Romiplostim market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Romiplostim is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Romiplostim market include AMGEN. etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Romiplostim, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Romiplostim, also provides the value of main regions and countries. Of the upcoming market potential for Romiplostim, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Romiplostim revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Romiplostim market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Romiplostim company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Romiplostim Segment by Company
AMGEN
Romiplostim Segment by Type
250μg/ 0.5 mL
500μg/ 1 mL
Romiplostim Segment by Application
Adults
Pediatric patients
Romiplostim Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Romiplostim status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Romiplostim key companies, revenue, market share, and recent developments.
3. To split the Romiplostim breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Romiplostim market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Romiplostim significant trends, drivers, influence factors in global and regions.
6. To analyze Romiplostim competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Romiplostim market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Romiplostim and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Romiplostim.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Romiplostim industry.
Chapter 3: Detailed analysis of Romiplostim company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Romiplostim in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Romiplostim in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Romiplostim market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Romiplostim is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Romiplostim is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Romiplostim market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Romiplostim is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Romiplostim market include AMGEN. etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Romiplostim, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Romiplostim, also provides the value of main regions and countries. Of the upcoming market potential for Romiplostim, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Romiplostim revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Romiplostim market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Romiplostim company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Romiplostim Segment by Company
AMGEN
Romiplostim Segment by Type
250μg/ 0.5 mL
500μg/ 1 mL
Romiplostim Segment by Application
Adults
Pediatric patients
Romiplostim Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Romiplostim status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Romiplostim key companies, revenue, market share, and recent developments.
3. To split the Romiplostim breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Romiplostim market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Romiplostim significant trends, drivers, influence factors in global and regions.
6. To analyze Romiplostim competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Romiplostim market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Romiplostim and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Romiplostim.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Romiplostim industry.
Chapter 3: Detailed analysis of Romiplostim company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Romiplostim in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Romiplostim in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
195 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Romiplostim Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Romiplostim Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Romiplostim Market Dynamics
- 2.1 Romiplostim Industry Trends
- 2.2 Romiplostim Industry Drivers
- 2.3 Romiplostim Industry Opportunities and Challenges
- 2.4 Romiplostim Industry Restraints
- 3 Romiplostim Market by Company
- 3.1 Global Romiplostim Company Revenue Ranking in 2024
- 3.2 Global Romiplostim Revenue by Company (2020-2025)
- 3.3 Global Romiplostim Company Ranking (2023-2025)
- 3.4 Global Romiplostim Company Manufacturing Base and Headquarters
- 3.5 Global Romiplostim Company Product Type and Application
- 3.6 Global Romiplostim Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Romiplostim Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Romiplostim Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Romiplostim Market by Type
- 4.1 Romiplostim Type Introduction
- 4.1.1 250μg/ 0.5 mL
- 4.1.2 500μg/ 1 mL
- 4.2 Global Romiplostim Sales Value by Type
- 4.2.1 Global Romiplostim Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Romiplostim Sales Value by Type (2020-2031)
- 4.2.3 Global Romiplostim Sales Value Share by Type (2020-2031)
- 5 Romiplostim Market by Application
- 5.1 Romiplostim Application Introduction
- 5.1.1 Adults
- 5.1.2 Pediatric patients
- 5.2 Global Romiplostim Sales Value by Application
- 5.2.1 Global Romiplostim Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Romiplostim Sales Value by Application (2020-2031)
- 5.2.3 Global Romiplostim Sales Value Share by Application (2020-2031)
- 6 Romiplostim Regional Value Analysis
- 6.1 Global Romiplostim Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Romiplostim Sales Value by Region (2020-2031)
- 6.2.1 Global Romiplostim Sales Value by Region: 2020-2025
- 6.2.2 Global Romiplostim Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Romiplostim Sales Value (2020-2031)
- 6.3.2 North America Romiplostim Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Romiplostim Sales Value (2020-2031)
- 6.4.2 Europe Romiplostim Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Romiplostim Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Romiplostim Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Romiplostim Sales Value (2020-2031)
- 6.6.2 South America Romiplostim Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Romiplostim Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Romiplostim Sales Value Share by Country, 2024 VS 2031
- 7 Romiplostim Country-level Value Analysis
- 7.1 Global Romiplostim Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Romiplostim Sales Value by Country (2020-2031)
- 7.2.1 Global Romiplostim Sales Value by Country (2020-2025)
- 7.2.2 Global Romiplostim Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Romiplostim Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Romiplostim Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Romiplostim Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Romiplostim Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Romiplostim Sales Value Growth Rate (2020-2031)
- 7.7.2 France Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Romiplostim Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Romiplostim Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Romiplostim Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Romiplostim Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Romiplostim Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Romiplostim Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Romiplostim Sales Value Growth Rate (2020-2031)
- 7.14.2 China Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Romiplostim Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Romiplostim Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Romiplostim Sales Value Growth Rate (2020-2031)
- 7.17.2 India Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Romiplostim Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Romiplostim Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Romiplostim Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Romiplostim Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Romiplostim Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Romiplostim Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Romiplostim Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Romiplostim Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Romiplostim Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Romiplostim Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Romiplostim Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Romiplostim Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Romiplostim Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Romiplostim Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Romiplostim Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Romiplostim Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 AMGEN
- 8.1.1 AMGEN Comapny Information
- 8.1.2 AMGEN Business Overview
- 8.1.3 AMGEN Romiplostim Revenue and Gross Margin (2020-2025)
- 8.1.4 AMGEN Romiplostim Product Portfolio
- 8.1.5 AMGEN Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

